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1. Introduction 
Atopic Dermatitis (AD) is a common inflammatory, pruritic skin disorder. It is a chronic 
disease with often relapse. Several factors including genetic predisposition, allergies to 
specific foods, irritant chemicals, and aeroallergens are thought to be the cause of AD. 
Diagnosis is difficult, and often occurs after ruling out other disorders with a clinical 
presentation resembling atopic dermatitis.  
2. Definition 
Atopic Dermatitis is a chronic relapsing inflammatory condition of the skin that occurs most 
frequently in childhood and may spontaneously resolve or continue throughout a person’s 
life span leading to lifelong sensitivity to irritants and allergens (Habif, 2008). It occurs as a 
result of several interrelated factors including genetic, immunologic and environmental 
issues, which ultimately cause a disruption in the epidermal barrier function leading to the 
development of dry, pruritic skin. The itching can be severe lasting throughout the day and 
worsening at night, which can lead to sleep disruptions and dramatically reduce the 
patients’ quality of life (Bieber, 2008). Episodes of AD can be triggered by events such as 
psychological stress, exposure to irritants and allergens or as a result of seasonal or climate 
changes (Habif, 2008). Additionally, patients with AD are at an increased risk of developing 
infections especially due to Staphylococcus Aureus and Herpes Simplex Virus, asthma and 
allergic rhinitis (Bieber, 2008). 
3. Epidemiology 
Over the past several decades’ industrialized nations have seen a dramatic rise in the 
incidence of AD (Ghazvini, et al. 2010). This disease occurs primarily in childhood affecting 
15-30% of children and 2-10% of adults. It most frequently begins in early childhood with 
45% of cases occurring within the first six months of life and 85% of cases diagnosed within 
the first five years (Bieber, 2008). 
4. Pathophysiology 
The pathophysiological mechanism of AD is multifactorial involving genetic, structural and 
immunological elements. The hallmark characteristic of AD is epidermal barrier dysfunction. 
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In normal individuals there are three factors that contribute to intact epidermal barrier 
function; structural proteins, lipids and proteases. Alterations in these components contribute 
to epidermal barrier dysfunction in AD patients. Additionally, genetic dysfunctions can be 
classified into two distinct groups; mutations occurring in genes encoding for epithelial 
structures and mutations occurring in genes encoding for elements of the immune system 
(Bieber, 2008). Lastly, immunological dysfunction appears to play a critical role in the 
pathogenesis of AD and involves alterations in T-cells, B-cells, eosinophils and IgE production.  
4.1 Structural factors 
There are several factors that lead to epidermal barrier dysfunction including changes in the 
stratum corneum, decreases in lipid levels and loss of function of a crucial protein called 
filaggrin. This is compounded by alterations in the expression of enzymes, such as 
peptidases within the epidermal layer leading to further breakdown of this protective 
barrier. Ultimately, the disruption of the epidermal barrier facilitates the penetration of 
environmental allergens and promotes allergic skin inflammation (Bieber 2008; Caubet & 
Eigenmann 2010).  
4.2 Genetic factors 
Researchers have identified several candidate genes that contribute to both the structural 
and immunological dysfunctions seen in AD. There is a genetically determined dominance 
of Th2 cells, which produce cytokines including Interleukin-4 (IL-4), Interleukin-5 (IL-5) and 
Interleukin-13 (IL-13). These cytokines play a role in the synthesis of IgE, which is 
upregulated in 85% of patients with AD. Additionally, there is a loss of function mutation in 
the gene encoding for the protein filaggrin, which is a crucial protein in cutaneous barrier 
function (Bieber 2008; Caubet & Eigenmann, 2010).  
4.3 Immunological factors 
The immunological factors that contribute to AD are multifactorial and complex. As stated 
previously, disruptions in the epidermal barrier facilitate the penetration of allergens. These 
allergens are presented to the Langerhans Cells (LCs) located within the epidermal layer, 
which migrate to the lymphoid organs where they present the allergen to the Th2 cells. 
(Callard & Harper 2007) Additionally, activated dendritic cells serve to stimulate memory 
Th2 cells and migrate to the lymph nodes where they further increase the systemic pool of 
Th2 cells by stimulating naïve T-cells. This increase in circulating T-cells results in the 
development of skin lesions through the production of inflammatory cytokines IL-4, IL-13, 
IL-5 and IL-12. Further promotion of the inflammatory response is modulated by Th2 cells 
through the upregulation of adhesion molecules on endothelial cells and increases in high 
affinity receptors for IgE on LCs and other antigen presenting cells. Lastly, eosinophils 
appear to play a role through secretion of cytolytic proteins resulting in further damage to 
the epithelial cells (Caubet & Eigenmann 2010). 
Other immunological factors that contribute to the pathogenesis of the disease include a 
down regulation of toll-like receptors (TLRs) within the epidermal cells. These TLRs serve to 
bind bacterial, fungal and viral structures leading to the activation of epithelial cells to 
produce antimicrobial peptides. These receptors are down regulated in the presence of IL-4, 
IL-13 and IL-10 in patients with AD The result is patients are at an increased risk of 
developing skin infections and are often colonized with Staphylococcus Aureus (Bieber, 2008).  
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5. Clinical presentation 
The clinical appearance of AD varies with disease severity. At all stages, patients have dry 
skin. Intensely pruritic, erythematous papules associated with exudates are seen in the acute 
phase of AD in infants. In the infantile stage (0-2 years old), the distribution of the rash is 
normally located on the face, chin, cheeks, scalp, trunk and extensor surfaces, but not on the 
nose or the diaper area (Deshazo, 2009). As the disease becomes more chronic, there is 
associated lichenification and the distribution of the rash is mostly seen on the wrists, ankles 
and neck in the childhood stage (2 years old-puberty) (Deshazo, 2009; Lipozencic, 2010). 
Approximately, 40% of childhood AD persists into adulthood (Bettrani, 2007). The 
distribution of rash in adults is similar to the childhood form mostly noticeable on the upper 
arms, back, wrists, dorsa of hands, fingers, feet and toes (Deshazo, 2009). The presence of 
pustules within areas of dermatitis suggests a secondary infection. Lesions with a less 
distinct distribution should prompt a search for an alternative diagnosis. 
6. Diagnosis 
The diagnosis of atopic dermatitis is based on a constellation of clinical signs and 
symptoms, physical examination and history. Laboratory tests are unnecessary and skin 
biopsy has been found to be little value, but they can exclude other diagnosis in adults. 
Although the majority of AD patients have elevated total serum IgE, up to 30% of these 
patients have normal total serum IgE and show no allergic sensitization to food or 
aeroallergens (Schmid-Grendelmeier, et al. 2005). However, monitoring of IgE remains a 
nonspecific finding of AD. 
Normally, diagnosis is confirmed by chronicity of symptoms, pruritis, and age-specific 
morphology and distribution of symptoms (Ong P, et al. 2008). However, well-defined 
criteria are important in the diagnosis of AD and diagnostic criteria developed by Hanifin 
and Rajka are widely accepted (see Table 1). The American Academy of Dermatology has 
also developed diagnostic criteria for AD (Leung & Hong, 2007). Please see Table 2.  
There are many exacerbating factors that are triggers, which can expedite the progress of 
inflammation. These triggers are found in food allergens, bacteria, viruses, stress and 
opportunistic pathogens. One of the major triggers is the microorganism Staphylococcus 
Aureus due to the fact that is organism secretes a toxin which can stimulate action of T cells 
(Ghazvini, et al. 2010). Among viruses, herpes simplex virus has been identified as one of 
the possible triggers of AD (Ghazvini, et al. 2010). Diagnostic testing is mainly utilized to 
determine specific allergens that may be causing the condition. These tests include: 
- Allergy or skin prick test – a positive prick test indicates the presence of IgE antibodies 
specific for a certain antigen. However, the positive predictive value is only 50%, which 
means a patient who has a positive test should undergo confirmatory testing through 
food challenges (Ghazvini, et al. 2010). 
- Atopy patch test- an atopy patch test (APT) is currently used to evaluate allergen 
without comparison with another accurate and reliable method, because no gold 
standard exists for aeroallergen provocation in AD. The APT is presumed to reflect 
delayed-phase clinical reactions. The patch test is performed by applying a patch 
consisting of large test chambers containing allergens. The patch is applied to the back 
for 48-72 hours on areas that are affected by AD or have not been treated with topical 
creams or ointments (Akdis, et al. 2006; Lipozencic, 2010).  
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- Food challenge – This is the most accurate test to diagnose allergy to food; skin 
reactions are expected to present up to 24 hours after testing. There are three patterns of 
skin reactions which can be observed with this test: 
 Immediate type reactions such as urticaria, erythema and angioedema may occur 
without worsening the AD symptoms and they may occur within a few minutes 
after food intake (Ong P, et al. 2008). 
 Pruritis may be noted after ingestion of food, which makes the patient scratch and 
may trigger AD. 
 Late reactions may occur as 6 to 8 hours after food ingestion (Ong P, et al. 2008). 
- Serum IgE measurement – Even though a larger number of AD patients have elevated 
serum IgE levels, approximately 30% have normal levels and do not present with 
allergic sensitization to allergens (Ong P, et al. 2008). 
- Skin biopsy – This is not necessary for diagnosis, however it may be essential for 
excluding other differentials of AD (see Table 3). 
 
Major Features Minor Features 
Pruritis Xerosis 
Typical morphology and distribution Cutaneous infections 
Flexural lichenification of linearity in 
adults 
Early age of onset 
Chronic or relapsing dermatitis 
Ichthyosis, palmar hyperlinearity and 
keratosis pilaris 
Facial or extensor involvement in infants 
and children 
Nonspecific dermatitis of the hands or feet 
Personal or family history of atopy 
(asthma, atopic dermatitits, contact 
urticaria) 
Raised serum immunoglobulin (Ig) E levels 
 Nipple eczema 
 Pityriasis alba 
 
White dermatographism and delayed blanch 
response 
 Anterior subcapsular cataracts 
 Perifollicular accentuation 
 
Course influenced by 
environmental/emotional factors 
 Facial erythema or pallor 
 
Dennie-Morgan infraorbital folds, orbital 
darkening 
**At least 3 major and minor features must be present for a diagnosis of atopic dermatitis. 
Table 1. Hanifin-Rajka Diagnostic Criteria for Atopic Dermatitis (Ghazvini, et al. 2010) 
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Essential Features 
(must be present) 
Pruritis 
Eczema (with typical morphology for age) 
Chronic or relapsing history 
 
Important Features 
(seen in most cases; add support to 
diagnosis) 
Early age at onset 
Personal or family history of atopy or IgE 
reactivity 
Xerosis 
Cutaneous infections 
Nonspecific dermatitis of the hands or feet 
Elevated serum IgE levels 
Positive skin test for immediate-type allergy 
 
Associated Features 
(nonspecific; help suggest diagnosis) 
Atypical vascular response (facial pallor, 
white dermatographism) 
Keratosis pillaris, hyperlinearity of palms 
Pityriasis alba 
Nipple eczema 
Ocular or periorbital changes, including 
anterior subcapsular cataracts, Dennie-
Morgan infraorbital folds, orbital darkening 
Perioral or periauricular lesions 
Perifollicular accentuation, lichenification or 
prurigo lesions 
Table 2. Diagnostic Criteria for Atopic Dermatitis by the American Academy of 
Dermatology (Ong P, et al. 2008) 
 
Other dermatosis 
- Contact dermatitis 
- Irritant dermatitis 
- Nummular dermatitis 
- Seborrheic dermatitis 
- Psoriasis ichthyosis 
 
Immunodeficiency syndromes 
- Wiskott-Aldrich syndrome 
- Severe combined immunodeficiency 
syndrome with Omen’s 
- Immune dysregulation, 
polyendocrinopathy, enteropathy, X-
linked  
- Graft vs host disease 
- Dermatitis herpetiformis 
Infections 
- Dermatophytosis 
- Scabies 
 
Metabolic and nutritional deficiencies 
- Phenylketonuria 
- Zinc deficiency 
- Niacin deficiency 
- Pyridoxine deficiency 
Malignancies 
- T cell lymphoma/mycosis fungoides 
- Letterer-Siwe disease 
 
Table 3. Differential Diagnosis in Atopic Dermatitis (Deshazo, 2009)7. Treatment 
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7. Treatment 
7.1 Nonphamacological interventions 
7.1.1 Dietary restrictions 
Hen’s egg, milk, wheat, soy, peanuts, nuts, and fish are responsible for 90% of the food 
allergy in patients with atopic dermatitis (Sircherer & Sampson, 1999). Avoiding these 
foods, and other foods suspected to cause flares may be helpful in reducing disease 
exacerbation, especially in children. Several studies identified the effects of dietary 
restriction in children with atopic dermatitis. One of these trials, conducted by Sloper and 
associates evaluated 78 children with atopic dermatitis. Patients were on a diet, which 
excluded cow’s milk, eggs, and foods known to trigger exacerbations. At the end of the 
trial, 64 patients experienced an improvement in their atopic dermatitis symptoms 
(Sloper, et al. 1991). Few studies in this meta-analysis used validated diagnostic criteria, 
which could have given skewed results. Because there are no precise findings in these 
studies, foods containing milk, eggs, or other known causes of disease flares should be 
avoided in patients with atopic dermatitis.  
7.1.2 Aeroallergen reduction 
Like with food allergens, different aeroallergens such as dust mites, pollen, mold, and 
animal dander can cause AD exacerbation. This exacerbation can be triggered either by 
inhalation or direct contact. Fungus and cockroaches have also been suspected (Michel, et al. 
2009; Simon-Nobbe, et al. 2008). There have been conflicting studies that show avoidance of 
aeroallergens, particularly dust mites, reduce disease symptoms. A double-blind, placebo 
controlled study using dust mite reducing measures in the home proved to improve the 
symptoms of atopic dermatitis (Tan, et al. 1996). By contrast, there are also trials that show 
the reduction in aeroallergens have no affect on symptoms of atopic dermatitis (Koopman, 
et al. 2001; Oosting, et al. 2002). Although the data varies, there is no harm in taking dust 
mite reducing measures. Aeroallergen reduction techniques that can be used include: using 
dust mite-proof encasings on pillows, mattresses, and box springs, washing bedding in hot 
water weekly, removal of bedroom carpet, and decreasing indoor humidity levels with air 
conditioning (Arlian & Platts-Mills, 2001).  
7.1.3 Detergent and chemical avoidance 
Because there is a higher chance of skin irritation in patients with atopic dermatitis, it is 
important to avoid those products or chemicals that can cause disease exacerbation 
(Nassif, et al. 1994). Certain soaps, fabric softeners, perfumes, cosmetics, and lotions 
contain alcohol and other ingredients that can be irritating to the skin of those patients 
with AD. These products can induce the itch-scratch cycle and worsen symptoms. It is 
suggested that laundry detergents containing enzymes can also worsen symptoms. A 
blinded crossover trial of 25 adults looked at the affect on atopic dermatitis symptoms 
with enzyme-enriched detergent, and a control detergent, which contained no enzymes. 
Although no diagnostic criteria were described in the trial, the SCORAD index was used 
to evaluate the patients’ severity of symptoms. There was no statistical difference in 
symptomatic relief between the two groups of patients (Andersen, et al. 1998). However, 
enzyme-enriched products should be avoided in patients with known hypersensitivity to 
enzyme proteins.  
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7.1.4 Phototherapy 
The use of natural sunlight for the treatment of atopic dermatitis has been shown to be 
beneficial, but sunburn should be avoided. If sunlight occurs in the presence of high 
humidity, or heat which triggers sweating, aggravation of symptoms can occur. 
Ultraviolet (UV) light (UVB, narrowband UVB, and high-intensity UVA) therapy can be 
useful in adjunct with other treatments options for patients. Topical glucocorticoid 
therapy, high-dose UVA1 phototherapy, and UVA-UVB phototherapy were compared in 
patients with atopic dermatitis. This was a randomized, multi-center trial that found 
significant differences in favor of high-dose UVA1 and fluocortolone therapy were 
observed (p < 0.0001), as compared with UVA-UVB therapy. At day 10, high-dose UVA1R 
was superior to fluocortolone (p < 0.002) therapy. (Krutmann, et al. 1998). There are also 
several small trials that look at specific wavelengths of and equipment for UV therapy. 
Chemophototherapy, psoralen with UVA (PUVA), has also been shown to be effective, 
but should be limited to those patients with widespread AD. Comparison studies with 
PUVA are limited. Short-term adverse events of UV phototherapy are mild and include: 
erythema, pruritis, and pigmentation. Potential long-term adverse effects include: 
premature skin aging, and cutaneous malignancies (Leung, et al. 2004). UV phototherapy 
is proven to be an effective method of therapy, because of this it is usually used as a 
second or third line of treatment.  
7.1.5 Psychological approaches 
Patients with atopic dermatitis are shown to have significant issues with anxiety, anger, and 
emotional stress (Bender 2002). They usually respond to embarrassment, frustration, 
anxiety, or other upsetting events with increased pruritis and scratching (Kodama, et al. 
1999). Although emotional factors do not cause atopic dermatitis, studies show that 
psychological techniques, such as stress reduction approaches, behavior modifications, and 
group counseling sessions may reduce the exacerbation of atopic dermatitis, particularly 
those prone to habitual scratching (Melin, et al. 1986).  
7.2 Pharmacological therapies 
7.2.1 Nonprescription therapies 
7.2.1.1 Antihistamines 
Oral antihistamines are usually recommended for pruritis. However, a recent study of 16 
trials showed no little evidence associated with the relief of pruritis with sedating or non-
sedating antihistamines (Klein & Clark, 1999). These observations, however, do not exclude 
the possibility that individual patients may benefit from antihistamines. Because pruritis can 
be worse at night, oral histamines have been beneficial at bedtime for their sedative 
properties in patients experiencing symptoms, and can be used as a short-term adjuvant to 
topical therapy (Kristal & Klein, 2000). The first generation antihistamines, hydroxyzine, 
diphenhydramine, and cyproheptadine all have sedative effects, but it is shown 
hydroxyzine to be more effective than the latter (Denman, 1986; Leung, et al. 1998). Newer 
generation antihistamines ceterizine, loratadine, and fexofenadine may not be beneficial 
since they lack the sedating properties of the first generation antihistamines. Topical 
antihistamines should be avoided to the risk of irritating the skin further (Shelley, et al. 
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1996). Common side effects of antihistamines include: sedation, dry mouth, constipation, 
blurred vision, and dizziness.  
7.2.1.2 Coal tar preparations 
Coal tar has been used to treat skin disorders for centuries. Although the exact pharmacologic 
effects are unknown, it is thought coal tar has antibacterial, antifungal, antipruritic, and 
keratoplastic effects (Andrew & Moses, 1999; Grupper, 1971; Lavker, et al. 1981). There is a 
theoretical risk that coal tar being a carcinogen based on observational studies of workers who 
use tar components in their occupation, however there have been no increase in cancer with 
clinical use (Callen, et al. 2007). Coal tar preparations have many disadvantages. Their odor, 
dark staining color, and side effects make them less desirable to patients. Coal tar comes in a 
variety of formulations, including creams, gels, shampoos, lotions and soaps. Newer 
formulations make the preparations more tolerable than older versions (Niordson & Stahl, 
1985). It is suggested that coal tar be applied at night to avoid the odor and staining of daytime 
clothing. Adverse effects associated with coal tar preparations include burning, stinging, 
folliculitis, and photosensitization (Kristal & Klein, 2000).  
7.2.1.3 Emollients 
Xerosis contributes to microfissures and cracks which can introduce microbes and allergens 
under the skin. This usually becomes exacerbated in the cold, dry winder months. Because 
AD is characterized by a decrease in skin barrier function, moisturizing and skin protection 
play an important role in the disease. Emollients have long been used for this. Although 
emollients have not been found to improve atopic dermatitis directly, they are a vital source 
of skin hydration and protection for these patients. The moisturizing aids are available in 
the forms of lotions, creams, and ointments, and are usually used in conjunction with 
corticosteroids. Formulations that contain certain dyes, alcohols, or fragrances can 
exacerbate atopic dermatitis and should be avoided. Because lotions are less viscous than 
the other formulations, they contain more water, which can cause an evaporative effect 
causing further skin drying. Ointments may interfere with appropriate sweat removal and 
result in sweat retention dermatitis. Emollients are better at maintaining skin hydration 
when applied after the patient soaks in a lukewarm bath.  
7.2.2 Prescription therapies 
7.2.2.1 Topical preparations 
7.2.2.1.1 Topical corticosteroids 
Topical corticosteroids have been a standard for treatment of atopic dermatitis and other 
skin disorders for years. Clinicians who are not familiar with topical corticosteroids can be 
challenged when providing care, due to the various strengths and formulations in which 
these medications are available. The decision to use a more or less potent corticosteroids 
depends on the severity of the dermatitis, location of the lesions, and the type of skin 
involved. Based on their vasoconstrictor assays, there are six potentcies of topical 
corticosteroids that are available though prescription, please refer to Table 4. Potency of 
topical corticosteroids depends on the concentration of the medication, but also the delivery 
vehicle. For example, betamethasone valerate ointment is considered more potent than a 
foam or cream containing the same medication. In general, the lowest potency that will 
control symptoms should be used. Low potency corticosteroids are recommended for the 
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Group 1: Super-High Potency Vehicle 
Betamethasone dipropionate augmented 0.05% Gel, lotion, ointment 
Clobetasol propionate 0.05% Cream, gel, foam, ointment, solution 
Fluocinonide 0.1% Cream 
Halobetasol propionate 0.05% Cream, ointment 
Group 2: High Potency Vehicle 
Amcinonide 0.1% Ointment 
Betamethasone dipropionate 0.05% augmented Cream 
Betamethasone dipropionate 0.05% Ointment 
Desoximetasone 0.25% Cream, gel, ointment 
Desoximetasone 0.05% Gel 
Diflorasone diacetate 0.05% Ointment 
Fluocinonide 0.05% Cream, gel, ointment, solution 
Halcinonide 0.1% Cream, ointment 
Mometasone furoate 0.1% Ointment 
Triamcinolone acetonide 0.5% Ointment 
Group 3: Medium-High Potency Vehicle 
Amcinonide 0.1% Cream, lotion 
Betamethasone dipropionate 0.05% Cream 
Betamethasone valerate 0.1% Ointment 
Desoximetasone 0.05% Cream 
Diflorasone diacetate 0.05% Cream 
Fluocinonide emollient 0.05% Cream 
Fluticasone propionate 0.005% Ointment 
Triamcinolone acetonide 0.1% Ointment 
Triamcinolone acetonide 0.5% Cream 
Group 4: Medium Potency Vehicle 
Betamethasone valerate 0.12% Foam 
Fluocinolone acetonide 0.025% Ointment 
Hydrocortisone valerate 0.2% Ointment 
Mometasone furoate 0.1% Cream, lotion 
Triamcinolone acetonide 0.1% Cream 
Group 5: Medium-Low Potency Vehicle 
Betamethasone dipropionate 0.05% Lotion 
Betamethasone valerate 0.1% Cream 
Desonide 0.05% Ointment 
Fluocinolone acetonide 0.025% Cream 
Flurandrenolide 0.05% Lotion 
Fluticasone propionate 0.05% Cream 
Group 6: Low Potency Vehicle 
Alclometasone Desonate 0.05% Cream, ointment 
Fluocinolone acetonide 0.01% Oil, cream,  
Desonide 0.01%, 0.05% Cream, gel, foam, lotion 
Table 4. Topical Steroids Preparations 
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face, eyelids, genitalia, and sensitive areas, as well as on young children and infants (Leung 
& Barber, 2003). More potent corticosteroids are used on other areas of the body in adults 
and children over 12 years of age.  
The dosing application of topical corticosteroids is important in the management of the 
disease, but there are limited trials on the optimal dose. Potent topical corticosteroids should 
be used for the shortest duration of time and an emollient used in combination during flare-
ups to prevent steroid-related side effects (Akdis, et al. 2006). Corticosteroids should be 
applied once to twice a day; frequent use does not improve efficacy and increases the risk of 
side effects (Bleehen, et al 1995; Leung & Barber, 2003). The risk of adverse reactions 
depends on the drug potency, skin integrity, and length of treatment (Fleischer, 1999). It is 
the clinician’s responsibility to balance the need for a potent corticosteroid with the potential 
for adverse reactions. Adverse effects of topical corticosteroids can be local or systemic. The 
latter, which occurs rarely, include adrenal suppression, Cushing’s syndrome, cataracts, and 
glaucoma (Correale, et al. 1999; Ruiz-Maldonado, et al. 1982; Stoppoloni, et al. 1983). Local 
adverse reactions include skin atrophy, contact dermatitis related to the vehicle, 
depigmentation, rosacea, steroid acne, and folliculitis (Correale, et al. 1999; Fleischer, 1999; 
Raimer, 2000). Treatment with topical corticosteroids can also reduce the colonization of S. 
Aureas, which may trigger exacerbations (Lipozencic & Wolf, 2007).  
7.2.2.1.2 Topical calcineurin inhibitors 
Pimecrolimus and tacrolimus are topical immunosuppresants that selectively inhibit the 
activation of T cells by inhibiting calcineurin, an enzyme required for the transcription of 
certain genes that code for specific inflammatory cytokines (Bornhovd, et al. 2002; 
Grassberger, et al. 2009). These are not recommended as first-line therapy or for mild atopic 
dermatitis. Pimecrolimus cream 1% and Tacrolimus ointment 0.03% are recommended for 
second-line therapy for mild to moderate AD in non-immunocompromised patients over 
two years old who have not been successful with other topical treatments.  
Short-term (up to four years) treatment with Tacrolimus has been shown safe and effective 
in children older than two years of age. In a 12-week randomized, vehicle-controlled, double 
blind, multicenter study of 351 children, 2 to 15 years of age, with moderate to severe atopic 
dermatitis, tacrolimus ointment (0.03% and 0.1% concentrations) was safe and significantly 
more efficacious than the vehicle (Paller, et al. 2001). Studies also show that the calcineurin 
inhibitors are more effective that topical cortical steroids. In a multicenter, randomized, 
double-blind, parallel-group comparison of tacrolimus ointment 0.03% and 0.1% with 
hydrocortisone acetate ointment 1% involved 560 children 2 to 15 years of age (Reitamo, et 
al. 2002). Both concentrations of tacrolimus were significantly more effective than 
hydrocortisone acetate.  
Pimecrolimus has also shown similar results to tacrolimus. Two identically designed, 
multicenter, randomized, controlled trials compared pimecrolimus cream 1% with vehicle in 
403 children 2 to 17 years of age. Both groups received treatment twice daily for 6 weeks. 
Results showed significant alleviation of symptoms and signs with pimecrolimus compared 
with the vehicle (Van Leent, et al. 1998.)  
Adverse effects of these two agents are similar. The most common adverse reactions are 
mild to moderate transient burning, stinging, itching, and erythema at the application site, 
which tends to resolve after the first few days of treatment (Bekersky, et al. 2001; Kang, et al. 
2001; Paller, et al. 2001; Reitamo, et al. 2002; Soter, et al. 2001). They are, however, 
contraindicated in pregnant or breast feeding women. These agents have been studied for 
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short term use (two years for pimecrolimus and 4 years for tacrolimus) and have been shown 
to have favorable outcomes, but have been advised that they be used in accordance to their 
guidelines due to the potential cancer risk. Long term studies for these drugs are still needed.  
7.2.2.2 Systemic immunosuppressants 
There are those individuals in which topical steroid use does not result in complete 
remission. As result, systemic immunosuppressant along with novel therapeutic options are 
warranted for severe refractory cases to provide increase in therapeutic options with 
effective remission rates and limited adverse effects. These subsets of patients should be 
referred to a specialist (i.e., dermatologist or allergist) for further evaluation. Severe atopic 
dermatitis may be described as the presence of widespread skin lesions or physically and/or 
emotionally disabling disease that significantly compromises a patient’s quality of life. The 
following will describe available systemic therapies for atopic dermatitis. 
7.2.2.2.1 Corticosteroids 
Systemic corticosteroids are not recommended for chronic or maintenance treatment of 
atopic dermatitis due to many common side effects associated with their use and possible 
rebound flaring upon discontinuation (Akdis et al, 2006). Typical side effects include; 
osteoporosis, cataracts, growth suppression, and poor wound healing. A short course of 
systemic corticosteroids with taper is recommended to abort an acute flare-up. 
Recommended dosing with prednisone is 40 to 60 mg daily for three to four days followed 
by 20 to 30 mg daily for three to four days can be beneficial. 
7.2.2.2.2 Cyclosporine 
Cyclosporine has proven beneficial in attenuating exacerbations in adults and children with 
severe atopic dermatitis. It also may be used for intermittent chronic not just short-term 
therapy. Cyclosporine is classified as a calcineurin inhibitor, which blocks T cell activation. 
A dose of 5mg/kg/day divided every 12 hours has been evaluated. Monitoring of trough 
levels, renal, and hepatic function is essential. A taper by 1mg/kg/day every one to three 
months is recommended. (Sowden et al, 1991; Brazelli et al, 2002). Common side effects 
associated with cyclosporine include increased risk of infection, malignancy, nephrotoxicity, 
hypertension, and seizures. 
7.2.2.2.3 Interferons 
Interferon-gamma (IFN-gamma) works by suppressing T helper cell activity along with 
other immunomodulatory effects (Schmitt 2007). Interferon-gamma (IFN-gamma) has 
shown varying results in the treatment of severe atopic dermatitis although a couple of trials 
have shown a reduction in symptoms and body surface involvement (Hanifin et al 1993). 
Side effects that may occur include granulocytopenia, fever/chills, myalgias, headache, and 
inject site pain. 
Several biological therapies have been studied for severe atopic dermatitis and only a few 
have shown benefit in small subset of patients. Further studies are necessary before any of 
these medications can be routinely recommended. Some of the biological therapies that have 
been evaluated are Omalizumab, Rituximab, Infliximab, Etanercept, Alefacept, and 
Mepolizumab (Graves et al 2007).  
7.2.2.2.4 Antimetabolites, azathiaprine, and methotrexate 
Antimetabolites azathioprine and methotrexate have shown usefulness in severe atopic 
dermatitis. Azathioprine is an antagonist of purine metabolism that inhibits T cell 
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proliferation. Methotrexate is a folic acid antagonist that inhibits reactions and promotes 
release of adenosine. It also inhibits lymphocyte proliferation. Adverse effects associated 
with azathioprine and methotrexate are myelosupression, hepatotoxicity, gastrointestinal 
disturbances, and increased risk of infection. Monitoring of hematologic and liver function 
tests is mandatory (Hon et al 2009; Weatherhead et al 2007).  
7.3 Emerging therapies 
As discussed, atopic dermatitis is an important skin disorder that leads to significant costs 
and morbidity to patients, families, and society. Effective therapeutic agents are limited in 
number, and all have side effects that impede successful long-term use. Consequently, there 
is a high medical need for better therapies. Bimosiamose, nanocrystalline silver cream, 
phosphodiesterase-4 inhibitors, and IL-4/IL-3 receptor blockers are considered here. 
7.3.1 Bimosiamose 
Bimosiamose is a selectin antagonist that blocks the initial slowing of leukocyte traffic, 
preventing leukocytes from migrating into the tissue, and may alter cell activation and cell-
cell signalling pathways. Currently Bimosiamose is in Phase II clinical testing for asthma, 
psoriasis, and atopic dermatitis (Revotar Biopharmaceuticals 2011). 
7.3.2 Nanocrystalline silver cream 
Nanocrystalline Silver Cream completed preliminary studies evaluating its use in atopic 
dermatitis. Silver has proven for decades to be an effective antimicrobial agent. It has been 
the active ingredient for the treatment of burns and other wounds. It has also demonstrated 
anti-inflammatory activity in animal studies. Human studies are currently in Phase II trials 
evaluating nanocrystalline silver cream applied twice daily using placebo, 0.5% or 1% cream 
(ClinicalTrials.gov 2005). 
7.3.3 Phosphodiesterase-4 Inhibitors 
Phosphodiesterases play a key role in degrading cAMP, which is an important process in 
virtually all the cell types involved in the pathophysiology of allergic and inflammatory 
diseases including asthma and chronic obstructive pulmonary disease (COPD), but also skin 
diseases such as psoriasis and atopic dermatitis. PDE-4 is the major and most abundant in 
almost all inflammatory and immune cells. PDE-4 suppresses several pro-inflammatory 
mechanisms like cytokine generation and secretion, IgE production, proliferation, and 
histamine generation just to name a few. Topical and systemic therapies are being studied. 
One general problem is the group associated side effect profile with nausea, emesis, and 
enhanced gastric acid production being the most critical commonly occurring with systemic 
therapies. Some examples are topical Atizoram and orally Arofylline. The newly FDA 
approved Roflumilast (Darilesp®) for severe COPD is being investigated for its utility in 
atopic dermatitis (Baumer et al 2007).  
7.3.4 Interleukin receptor blockers 
Elevated IgE responses and eosinophilia is observed in many patients with atopic 
dermatitis. This is thought to reflect the increased expression of Th2 cytokines, in particular 
IL-4, IL-5, and IL-13. Cutaneous infiltration of activated T-cells and their release of cytokines 
are thought to be key events in the development of atopic dermatitis. There are three ways 
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of inhibition of IL-4; synthesis inhibitors, binding site inhibitors, and inhibiting intracellular 
signal transduction. Suplatast tosylate is an example of a synthesis inhibitor developed in 
Japan and may prove useful for steroid resistant asthma, but data about possible effects in 
atopic dermatitis are lacking. There are several compounds being studied as therapeutic 
agents inhibiting the binding site and signal transduction (Hennekes & Asadullah 2002). 
8. Complications 
If AD is not appropriately treated there can be several complications that can arise. It is 
shown that patients with atopic dermatitis are more susceptible to microorganisms, 
particularly S. aureus. Untreated lesions can result in bacterial infections, and acute 
inflammatory responses of the skin. Patients with atopic dermatitis can also present with 
eyelid dermatitis, nipple dermatitis, and cheilitis of the lips. Eyelid dermatitis and chronic 
blepharitis can result in visual impairment from corneal scarring. Other ocular 
complications include atopic keratoconjunctivitis, vernal conjunctivitis, and keratoconus 
(Leung, et al. 2003). Management of AD is important in the prevention of other conditions. 
9. Role of a clinician 
Patient education, in addition to treatment, is a factor that can drastically help improve 
the health of any patient. The healthcare practitioner plays a very important role in a 
patients’ improvement of atopic dermatitis. They can assist a patient in determining what 
the causative agent is, and provide counselling on how to avoid that particular agent. A 
physician’s knowledge on appropriate diagnosis and the available treatment options is 
very important in ensuring optimal care. As the drug experts, pharmacists are also 
responsible for the care of the patient. By providing practical advice concerning the 
appropriate use of drug products, such as topical corticosteroids and calcineurin 
inhibitors, compliance can be optimized and adverse effects minimized. In addition, the 
pharmacist can diminish the stress and anxiety often experienced by patients and 
caregivers, particularly parents of infants and children with atopic dermatitis. In addition, 
a pharmacist can advise undiagnosed or untreated patients’ on when it is necessary to 
receive treatment from a physician.  
10. Conclusion 
Atopic dermatitis is a condition that has no cure, but the main goal of treatment is to reduce 
disease flares and improve the patients’ quality of life. Avoidance of triggering factors, 
optimal skin care, and pharmacotherapy can produce control of exacerbations in patients. 
Although there is no cure, there are many safe and effective treatment options available. 
Corticosteroids remains the standard for therapy, but those unresponsive to corticosteroids 
have other options including systemic and topical immunomodulators, and non-
prescription agents.  
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